Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284551 | 1.00 | CETP (0.62) | CETPKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5224706 | 0.86 | CYP3A4 (0.61) | CETPCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6284357 | 0.86 | CYP3A4 (0.69) | CETPKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6286044 | 0.86 | CYP3A4 (0.69) | CETPKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6282558 | 0.83 | CYP3A4 (0.62) | CETPKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6277796 | 0.83 | CYP3A4 (0.62) | CETPKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6281757 | 0.80 | CYP3A4 (0.69) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL6283749 | 0.80 | CYP3A4 (0.57) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4861665 | 0.80 | CETP (0.44) | CETPKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6278278 | 0.80 | CYP3A4 (0.60) | CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | CETP 3376/4885KDM4E 4298/4885ALDH1A1 110/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | CETP 3376/4885KDM4E 4298/4885ALDH1A1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.